INCYTE CORP 8-K

What Happened
Incyte Corporation announced on March 6, 2026 (8‑K filing) that the U.S. FDA issued a Complete Response Letter (CRL) on February 27, 2026 for the supplemental Biologics License Application (sBLA) for Zynyz® (retifanlimab‑dlwr) 375 mg injection. The sBLA sought approval for an additional indication: treatment of adult patients with metastatic non‑small cell lung cancer (NSCLC) in combination with platinum‑based chemotherapy. The sBLA was supported by positive efficacy and safety data from the Phase 3 POD1UM‑304 trial (announced December 2024).

Key Details

• CRL date: February 27, 2026; 8‑K filed: March 6, 2026.
• Product: Zynyz (retifanlimab‑dlwr) 375 mg injection for metastatic NSCLC (combo with platinum chemo).
• Reason: CRL cites inspection findings at Catalent Indiana, LLC (Novo Nordisk affiliate), the third‑party fill‑finish facility referenced in the sBLA.
• Scope: FDA identified Catalent Indiana’s regulatory compliance as the sole approvability issue; FDA did not cite concerns with Zynyz’s efficacy/safety data or the third‑party drug substance manufacturer.
• Next steps: Incyte is working with the FDA and Catalent Indiana to address the CRL and support a potential sBLA resubmission.

Why It Matters
This CRL delays the potential regulatory approval and commercialization of Zynyz for NSCLC, which could affect future revenue growth tied to this label expansion. Importantly for investors, the issue reported by FDA is related to a third‑party manufacturing facility (fill‑finish) rather than the clinical efficacy or safety data from POD1UM‑304. That distinction means the company’s clinical case for approval remains intact, but approval timing now depends on corrective actions at Catalent Indiana and FDA acceptance of a resubmission.